Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$2.27
-$0.01(-0.44%)
At close: 4:00 PM EDT
$2.27
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous Close$2.28
Volume807.02K
Average Volume (3M)730.63K
Market Cap
$149.53M
Enterprise Value$1.26
Total Cash (Recent Filing)$230.43M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume633,109
30 Day Avg. Volume730,626
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.80Price Target Upside419.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic NK PlatformNkarta’s focus on off-the-shelf allogeneic NK cell therapies is a durable strategic edge: a scalable, standardized product reduces per-patient manufacturing complexity vs autologous approaches, supports broader commercial reach, and makes long-term partnerships and manufacturing scale more feasible.
Moderate LeverageModerate debt-to-equity (~0.26 TTM) indicates the company is not overly reliant on borrowings, which lowers near-term insolvency risk and preserves flexibility to raise equity or debt when needed. This structural balance sheet profile supports continued R&D investment without heavy interest burden.
Improving Loss TrendA multi-year reduction in net losses suggests improving cost discipline or operational efficiencies. Sustained improvement, if continued, can extend runway and reduce the magnitude of future financing needs, lowering long-term dilution risk and improving the prospect for advancing clinical programs.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (~-$87M to -$88M TTM) is a structural weakness: it forces reliance on external funding, increases dilution risk, and can constrain the pace of clinical development or commercialization unless offset by revenue or substantial financings.
Pre-revenue ModelThe absence of product revenue leaves the company dependent on pipeline progress and financing. This structurally limits visibility into long-term profitability, makes cash runway sensitive to trial outcomes, and raises execution risk until commercial sales are established.
Reliance On External FinancingDeclining shareholders' equity and an historical reliance on equity financings indicate structural funding risk: future capital needs may dilute existing holders, and repeated raises can divert management focus, constrain long-term strategic choices, and pressure governance and financing terms.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $149.53M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on May 12, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.016.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.36.
How many shares outstanding does Nkarta have?
Nkarta has 71,545,360 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -6.707%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (419.82% Upside)
$11.80 (419.82% Upside)
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.94%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(419.82% Upside)
Technical Analysis
Ownership Overview
20.64% Insiders
7.77% Mutual Funds
3.20% Other Institutional Investors
61.17% Public Companies and
Individual Investors